A carregar...
Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
Breast cancer is the most common cancer in a woman with a five-year survival of patients with metastatic disease is estimated at 23%. Ado-trastuzumab emtansine (T-DM1) is a HER2-antibody drug conjugate currently approved for the treatment of HER2-positive pre-treated metastatic breast cancer (BC). W...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6886650/ https://ncbi.nlm.nih.gov/pubmed/31824803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6036 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|